A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease.

Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in stage III and IV cancers.

By Kamal Choudhury and Mariam Sunny Feb 20 (Reuters) - Grail's shares plunged nearly 50% on Friday after the company said routine screening with its cancer blood test failed to significantly boost ...

Cancer is the No. 1 cause of line-of-duty deaths among firefighters, who are 9% more likely than the general population to be ...

"No cancer signal detected." The blood test results popped up in my online health portal without much fanfare. A doctor would chat about them with me later, congratulating me on the "phew"-worthy ...

Despite efforts by test maker Grail to highlight outcomes the company considers positive, some experts are warning against using the Galleri test and others like it.

HealthDay News — A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it. The test, called Galleri, failed to lower the number of ...

Grail said Galleri, its multi-cancer early detection test, failed to meet the primary endpoint of a recent trial. The stock slid 47%, to $54.20, in after-hours trading. Through market close, share ...

A large, three-year clinical trial designed to demonstrate how Grail’s blood test for early cancer detection could work in a broad population has preliminary results showing reduction in late-stage ...

A flurry of such tests that look for multiple cancers with a prick are in various stages of development. The one that is ...

GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.

Private companies are capitalizing on this quest for information. Grail’s Galleri blood test screens for more than 50 ...